GenSight Biologics Announces Annual General Meeting to Take Place on May 19, 2026

GenSight Biologics Announces the Filing of its 2025 Universal Registration Document

GenSight Biologics Reports Cash Position as of December 31, 2025, and Provides Business Updates

GenSight Biologics Announces Successful Fundraising Amounting to Nearly €2.9 Million

GenSight Biologics Announces Regulatory Authorization for Early Access Treatment with GS010/LUMEVOQ® in Israel

GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 2 Million

GenSight Biologics Announces Successful Fundraising Amounting to Nearly €2 Million

GenSight Biologics Reports Cash Position as of June 30, 2025

GenSight Biologics Announces the Closing of the Company’s c. €4 Million Private Placement

GenSight Biologics Announces Successful Completion of a Private Placement of Close to EUR 4 Million